95-15100. Availability of Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning a Test for Antibodies in Stool Specimens

[Federal Register Volume 60, Number 119 (Wednesday, June 21, 1995)]
[Notices]
[Page 32305]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-15100]



-----------------------------------------------------------------------


DEPARTMENT OF DEFENSE

Availability of Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning a Test for Antibodies 
in Stool Specimens

AGENCY: U.S. Army Medical Research and Materiel Command, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability of U.S. Patent Application SN 08/376,977, entitled ``Test 
for Antibodies in Stool Specimens,'' and filed January 23, 1995, for 
licensing. This patent has been assigned to the United States 
Government as represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, Fort Detrick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT:
Mr. John F. Moran, Patent Attorney, 301-619-2065 or telefax 301-619-
7714.

SUPPLEMENTARY INFORMATION: This invention provides a method for testing 
clinical samples suspected of containing systemic or mucosal antibodies 
to V. cholerae by coupling specific antigen to magnetic beads and 
exposing said beads to specimens suspected of containing specific 
antibodies. The method is particularly valuable for detecting mucosal 
antibodies in stool and can be used for detection of infection, 
indicating the immune status of individuals, and for epidemiological 
tracking.
    While assays such as ELISA are available for quantitating a 
systemic immune response, means for evaluating mucosal immune responses 
are less well developed when though it is believed that the immune 
response to V. cholerae is predominantly controlled by the mucosal 
immune system. Because of the rapid nature of the assay and the 
immediate treatment of the sample with protease inhibitors, problems 
related to specimen processing are minimized. The method of invention 
is rapid, inexpensive, can be performed by minimally trained personnel, 
and provides a means for testing of clinical samples in either a 
laboratory or field setting.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 95-15100 Filed 6-20-95; 8:45 am]
BILLING CODE 3710-08-M